Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
CANCER:
Marginal Zone Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (832
)
Diffuse Large B Cell Lymphoma (295
)
Mantle Cell Lymphoma (101
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
Non-Hodgkin’s Lymphoma (832
)
Diffuse Large B Cell Lymphoma (295
)
Mantle Cell Lymphoma (101
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Peripheral T-cell Lymphoma (48
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
›
Associations
(33)
Heatmap
News
Twitter
Trials
Reset Filters
Veri cancer hierarchy
x
x
x
x
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
umbralisib
Sensitive: A1 - Approval
umbralisib
Sensitive
:
A1
umbralisib
Sensitive: A1 - Approval
umbralisib
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
ibrutinib
Sensitive: A1 - Approval
ibrutinib
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
R-CVP
Sensitive: A2 - Guideline
R-CVP
Sensitive
:
A2
R-CVP
Sensitive: A2 - Guideline
R-CVP
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
R-CHOP
Sensitive: A2 - Guideline
R-CHOP
Sensitive
:
A2
R-CHOP
Sensitive: A2 - Guideline
R-CHOP
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
axicabtagene ciloleucel
Sensitive: A2 - Guideline
axicabtagene ciloleucel
Sensitive
:
A2
axicabtagene ciloleucel
Sensitive: A2 - Guideline
axicabtagene ciloleucel
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
copanlisib
Sensitive: A2 - Guideline
copanlisib
Sensitive
:
A2
copanlisib
Sensitive: A2 - Guideline
copanlisib
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
chlorambucil
Sensitive: A2 - Guideline
chlorambucil
Sensitive
:
A2
chlorambucil
Sensitive: A2 - Guideline
chlorambucil
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
ibritumomab tiuxetan
Sensitive: A2 - Guideline
ibritumomab tiuxetan
Sensitive
:
A2
ibritumomab tiuxetan
Sensitive: A2 - Guideline
ibritumomab tiuxetan
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
G-CHOP
Sensitive: A2 - Guideline
G-CHOP
Sensitive
:
A2
G-CHOP
Sensitive: A2 - Guideline
G-CHOP
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
tisagenlecleucel-T
Sensitive: A2 - Guideline
tisagenlecleucel-T
Sensitive
:
A2
tisagenlecleucel-T
Sensitive: A2 - Guideline
tisagenlecleucel-T
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
O-CVP
Sensitive: A2 - Guideline
O-CVP
Sensitive
:
A2
O-CVP
Sensitive: A2 - Guideline
O-CVP
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
INCB50465
Sensitive: B - Late Trials
INCB50465
Sensitive
:
B
INCB50465
Sensitive: B - Late Trials
INCB50465
Sensitive
:
B
MYD88 mutation
Marginal Zone Lymphoma
MYD88 mutation
Marginal Zone Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
CARD11 mutation
Marginal Zone Lymphoma
CARD11 mutation
Marginal Zone Lymphoma
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
KMT2D mutation
Marginal Zone Lymphoma
KMT2D mutation
Marginal Zone Lymphoma
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
ibrutinib
Resistant: C3 – Early Trials
ibrutinib
Resistant
:
C3
MYD88 L265P
Marginal Zone Lymphoma
MYD88 L265P
Marginal Zone Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
TNFAIP3 mutation
Marginal Zone Lymphoma
TNFAIP3 mutation
Marginal Zone Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
CD5 positive
Marginal Zone Lymphoma
CD5 positive
Marginal Zone Lymphoma
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
LDH elevation
Marginal Zone Lymphoma
LDH elevation
Marginal Zone Lymphoma
ViPOR
Sensitive: C3 – Early Trials
ViPOR
Sensitive
:
C3
ViPOR
Sensitive: C3 – Early Trials
ViPOR
Sensitive
:
C3
TNFAIP3 mutation
Marginal Zone Lymphoma
TNFAIP3 mutation
Marginal Zone Lymphoma
zanubrutinib
Sensitive: C3 – Early Trials
zanubrutinib
Sensitive
:
C3
zanubrutinib
Sensitive: C3 – Early Trials
zanubrutinib
Sensitive
:
C3
MYD88 mutation
Marginal Zone Lymphoma
MYD88 mutation
Marginal Zone Lymphoma
zanubrutinib
Sensitive: C3 – Early Trials
zanubrutinib
Sensitive
:
C3
zanubrutinib
Sensitive: C3 – Early Trials
zanubrutinib
Sensitive
:
C3
TP53 mutation + MET amplification + PD-L1 overexpression
Marginal Zone Lymphoma
TP53 mutation + MET amplification + PD-L1 overexpression
Marginal Zone Lymphoma
sintilimab
Sensitive: C4 – Case Studies
sintilimab
Sensitive
:
C4
sintilimab
Sensitive: C4 – Case Studies
sintilimab
Sensitive
:
C4
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
Marginal Zone Lymphoma
NOTCH2 mutation + NCOA4 mutation + PTEN mutation + EPHA3 mutation + KMT2D mutation
Marginal Zone Lymphoma
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
rituximab
Sensitive: C4 – Case Studies
rituximab
Sensitive
:
C4
BIRC3-MALT1 fusion
Marginal Zone Lymphoma
BIRC3-MALT1 fusion
Marginal Zone Lymphoma
R-CHOP
Sensitive: C4 – Case Studies
R-CHOP
Sensitive
:
C4
R-CHOP
Sensitive: C4 – Case Studies
R-CHOP
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
